Involvement of mast cells in systemic sclerosis

Japanese Journal of Clinical Immunology

Volumn 33, Issue 2, 2010, Pages 81-86

  Yukawa, Sonosuke ^a   Yamaoka, Kunihiro ^a   Sawamukai, Norifumi ^a   Shimajiri, Shohei ^a   Saito, Kazuyoshi ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Imatinib; Mast cell; Pulmonary arterial hypertension; Systemic sclerosis

Indexed keywords

BOSENTAN; CYCLOPHOSPHAMIDE; IMATINIB; IMMUNOGLOBULIN E; PROSTACYCLIN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADAPTIVE IMMUNITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MAST CELL; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC SCLEROSIS; ANIMAL; DISEASE MODEL; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; MOUSE; PULMONARY HYPERTENSION; SCLERODERMA, SYSTEMIC;

ADAPTIVE IMMUNITY; ANIMALS; ARTHRITIS, RHEUMATOID; BENZAMIDES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNITY, INNATE; MALE; MAST CELLS; MICE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SCLERODERMA, SYSTEMIC;

EID: 77953661570     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.33.81     Document Type: Review

References (28)

1. Galli SJ,z et al. : Mast cells in the development of adaptive immune responses. Nat Immunol Rev. 6 : 135-142, 2005.
2. Lee DM, et al. : Mast cells : a cellular link between autoantibodies and inflammatory arthritis. Science. 297 : 1689-1692, 2002.
3. Shin K, et al. : Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol. 182 : 647-656, 2009.
4. Ruoss SJ, et al. : Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest. 88 : 493-499, 1991.
5. Garbuzenko E, et al. : Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction : a direct role for mast cells in skin fibrosis. Clin Exp Allergy. 32 : 237-246, 2002. (Pubitemid 34429602)
6. Walker M, et al. : Mast cells and their degranulation in the Tsk mouse model of scleroderma. Proc Soc Exp Biol Med. 180 : 323-328, 1985. (Pubitemid 16201279)
7. McNeil HP, et al. : The mouse mast cell-restricted tetramer-forming tryptases mouse mast cell protease 6 and mouse mast cell protease 7 are critical mediators in inflammatory arthritis. Arthritis Rheum. 58 : 2338-2346, 2008.
8. Stevens RL, et al. : Protease-proteoglycan complexes of mouse and human mast cells and importance of their beta-tryptase-heparin complexes in inflammation and innate immunity. Immunol Rev. 217 : 155-167, 2007.
9. Nigrovic PA, et al. : Synovial mast cells : role in acute and chronic arthritis. Immunol Rev. 217 : 19-37, 2007.
10. Green MC, et al. : Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 82 : 493-512, 1976.
11. Menton DN, et al. : The ultrastructure of collagen in the dermis of tight-skin (Tsk) mutant mice. J Invest Dermatol 74 : 139-147, 1980.
12. Walker M, et al. : Mast cells and their degranulation in the Tsk mouse model of scleroderma. Proc Soc Exp Biol Med 180 : 323-328, 1985. (Pubitemid 16201279)
13. Walker MA, et al. : Inhibition of fibrosis in TSK mice by blocking mast cell degranulation. J Rheumatol 14 : 299-301, 1987.
14. Walker M, et al. : Ketotifen prevents skin fibrosis in the tight skin mouse. J Rheumatol 17 : 57-59, 1990. (Pubitemid 20070569)
15. Everett ET, et al. : The role of mast cells in the development of skin fibrosis in tight-skin mutant mice. Comp Biochem Physiol A Physiol 110 : 159-165, 1995.
16. Wang HW, et al. :Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma. Exp Dermatol 14 : 295-302, 2005.
17. Yamamoto T, et al. : Animal model of sclerotic skin. I : local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112 : 456-462, 1999. (Pubitemid 29171935)
18. Yamamoto T, et al. : Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. J Rheumatol 26 : 2628-2634, 1999.
19. Jaffee BD, et al. : Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol 77 : 1-12, 1983.
20. Claman HN, et al. : Chronic graftversus- host disease as a model for scleroderma. II.Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol 94 : 73-84, 1985.
21. Levi-Schaffer F, et al. : Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease. Bone Marrow Transplant 19 : 823-828, 1997. (Pubitemid 27207900)
22. Steen VD : Scleroderma renal crisis. Rheum Dis Clin North Am 29 : 315-333, 2003.
23. Badesch DB, et al. : Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med, 132 : 425-434, 2000.
24. Guillevin L, et al. : Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis, 65 : 392, 2006.
25. Tashkin DP, et al. : Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med, 354 : 2655-2666, 2006. (Pubitemid 43920839)
26. Distler JH, et al. : Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 56 : 311-322, 2007.
27. Akhmetshina A, et al. : Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 60 : 219-224, 2009.
28. Chung L, et al. : Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum. 60: 584-591, 2009.